Leading brokers name 3 ASX shares to buy today

Here's why brokers rate these ASX shares as buys…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

With so many shares to choose from on the ASX, it can be hard to decide which ones to buy. The good news is that brokers across the country are doing a lot of the hard work for you.

Three top ASX shares leading brokers have named as buys this week are listed below. Here's why they are bullish on them:

Business man marking buy on board and underlining it.

Image Source: Getty Images

Appen Ltd (ASX: APX)

According to a note out of Citi, its analysts have retained their buy rating and $17.10 price target on this artificial intelligence data services company's shares. Citi is sticking with Appen despite news that Amazon has launched a new SageMaker Ground Truth Plus service that uses an expert workforce to deliver high-quality training datasets faster. The broker believes that while competition in the Enterprise space may increase, competition with Appen's major technology customers shouldn't be impacted. The Appen share price is trading at $9.21 on Monday afternoon.

Australia and New Zealand Banking GrpLtd (ASX: ANZ)

A note out of Morgans reveals that its analysts have retained their add rating and $31.00 price target on this banking giant's shares. Morgans remains positive on the banking sector as a whole and believes there is potential for further capital management and generous dividends in the near term. Its analysts also expect rising interest rates to be supportive of earnings growth in the coming years. The ANZ share price is fetching $26.87 today.

ResMed Inc. (ASX: RMD)

Analysts at Macquarie have upgraded this medical device company's shares to an outperform rating with a $39.00 price target. While Macquarie acknowledges that supply chain issues are putting pressure on near term device supply, its analysts remain positive. This is due to an expected increase in industry volume growth from 2023 and market share gains for ResMed. Macquarie believes this will support revenue and earnings growth ahead of current analyst consensus estimates. The ResMed share price is trading at $36.29 on Monday.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of and has recommended Appen Ltd. The Motley Fool Australia owns shares of and has recommended Appen Ltd. The Motley Fool Australia has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Broker Notes

Person pointing at an increasing blue graph which represents a rising share price.
Broker Notes

2 ASX 200 stocks that could rise 50%

Morgans thinks the market is undervaluing these shares.

Read more »

Contented looking man leans back in his chair at his desk and smiles.
Broker Notes

Brokers name 3 ASX shares to buy right now

Here's why brokers are feeling bullish about these three shares this week.

Read more »

Dollar sign in yellow with a red falling arrow in front of a graph, symbolising a falling share price.
Broker Notes

6 ASX 200 shares downgraded by brokers this week

Brokers have reduced their ratings on TechnologyOne, Macquarie, 4DMedical, and others this week.

Read more »

A woman is excited as she reads the latest rumour on her phone.
Broker Notes

Could these ASX stocks really be set to double after crashing this week?

These companies are expected to rebound.

Read more »

A man in a sweatshirt holds two different phones to compare telco services.
Broker Notes

Forget Rio Tinto and buy this ASX copper share

Bell Potter thinks this stock could be a good alternative to the mining giant.

Read more »

A happy couple drinking red wine in a vineyard.
Broker Notes

2 ASX 200 shares newly upgraded this week

After major company news this week, one stock fell 39% while the other spiked 17%.

Read more »

Time to sell written on a clock.
Broker Notes

Sell alert! Why this expert is calling time on CBA shares

A leading analyst forecasts headwinds for CBA shares. But why?

Read more »

a couple consider the advice from a man with documents laid out on a table and the man holding a tablet in his hand.
Financial Shares

3 ASX 200 financial shares to sell: experts

ASX 200 financial shares are down 2.5% over six months and up 2.1% in 2026-to-date.

Read more »